Kenichiro Toritani1, Hideaki Kimura2, Reiko Kunisaki1, Jun Watanabe3, Chikara Kunisaki3, Atsushi Ishibe4, Sawako Chiba5, Yoshiaki Inayama5, Itaru Endo4. 1. Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Yokohama, Japan. 2. Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Yokohama, Japan hkim@yokohama-cu.ac.jp. 3. Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. 4. Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 5. Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan.
Abstract
BACKGROUND/AIM: The present study examined the utility of serum p53 antibody (Ab) for detecting colitis-associated cancer (CAC) in the era of immunosuppressive therapy. PATIENTS AND METHODS: Two hundred and fifty patients were analyzed, 219 had no carcinoma or dysplasia (Group non-CAC), and 31 had carcinoma or dysplasia (Group CAC). Serum p53 Abs were detected with an enzyme-linked immunosorbent assay. Immunohistochemical detection was performed in Group CAC. RESULTS: Immunosuppressive therapy was performed in 98.1% of Group non-CAC and 80.6% of Group CAC. There were no differences in serum p53 Abs positivity between Groups non-CAC and CAC (8.7% vs. 3.2%, p=0.30). p53 staining positivity was noted in 90.3% of Group CAC, and the rate of serum p53 positivity was significantly lower in patients with immunosuppressive therapy than in those without in Group CAC (0.0% vs. 16.7%, p=0.04). CONCLUSION: The utility of serum p53 Ab for detecting CAC is dubious in the era of immunosuppressive therapy. Copyright
BACKGROUND/AIM: The present study examined the utility of serum p53 antibody (Ab) for detecting colitis-associated cancer (CAC) in the era of immunosuppressive therapy. PATIENTS AND METHODS: Two hundred and fifty patients were analyzed, 219 had no carcinoma or dysplasia (Group non-CAC), and 31 had carcinoma or dysplasia (Group CAC). Serum p53 Abs were detected with an enzyme-linked immunosorbent assay. Immunohistochemical detection was performed in Group CAC. RESULTS: Immunosuppressive therapy was performed in 98.1% of Group non-CAC and 80.6% of Group CAC. There were no differences in serum p53 Abs positivity between Groups non-CAC and CAC (8.7% vs. 3.2%, p=0.30). p53 staining positivity was noted in 90.3% of Group CAC, and the rate of serum p53 positivity was significantly lower in patients with immunosuppressive therapy than in those without in Group CAC (0.0% vs. 16.7%, p=0.04). CONCLUSION: The utility of serum p53 Ab for detecting CAC is dubious in the era of immunosuppressive therapy. Copyright